• Conatumumab
    Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed...
    3 KB (212 words) - 21:08, 11 November 2023
  • List of drugs: Cm–Co
    compound solution of sodium lactate (INN) Compro Comtan Comtrex Comvax conatumumab (USAN, INN) conbercept (INN) Concentraid Conceptrol Concerta condoliase...
    7 KB (421 words) - 02:51, 27 September 2024
  • Thumbnail for Tumor necrosis factor
    Tumor necrosis factor
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    68 KB (8,829 words) - 00:50, 29 September 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    List of therapeutic monoclonal antibodies
    humanized PTK7 cancer Coltuximab ravtansine mab chimeric CD19 cancer Conatumumab mab human TRAIL-R2 cancer Concizumab Alhemo mab humanized tissue factor...
    136 KB (4,020 words) - 06:13, 27 September 2024
  • Thumbnail for Tumor necrosis factor superfamily
    Tumor necrosis factor superfamily
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    8 KB (316 words) - 13:53, 10 September 2024
  • Thumbnail for TNF receptor superfamily
    TNF receptor superfamily
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    8 KB (501 words) - 13:55, 10 September 2024
  • Thumbnail for Lymphotoxin alpha
    Lymphotoxin alpha
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    24 KB (2,809 words) - 11:12, 20 August 2024
  • Thumbnail for Tumor necrosis factor receptor 1
    Tumor necrosis factor receptor 1
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    20 KB (2,146 words) - 16:24, 21 August 2024
  • Thumbnail for Tumor necrosis factor receptor 2
    Tumor necrosis factor receptor 2
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,387 words) - 13:47, 4 September 2024
  • Thumbnail for Lymphotoxin beta
    Lymphotoxin beta
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,494 words) - 19:35, 4 September 2024
  • Lymphotoxin
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,459 words) - 03:14, 30 October 2022
  • Thumbnail for Lymphotoxin beta receptor
    Lymphotoxin beta receptor
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,508 words) - 17:56, 19 August 2022
  • Indium (111In) altumomab pentetate
    Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
    3 KB (129 words) - 01:04, 19 July 2023
  • Minretumomab
    Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
    5 KB (368 words) - 15:29, 21 August 2024
  • Thumbnail for Naptumomab estafenatox
    Naptumomab estafenatox
    Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
    4 KB (241 words) - 13:42, 14 July 2024